Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis

V. A. Salvo, S. M. Boue, J. P. Fonseca, S. Elliott, C. Corbitt, B. M. Collins-Burow, T. J. Curiel, S. K. Srivastav, B. Y. Shih, C. Carter-Wientjes, C. E. Wood, P. W. Erhardt (+4 others)
2006 Clinical Cancer Research  
Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II, and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for
more » ... ach cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (À53.4%) and BG-1 cells (À73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.
doi:10.1158/1078-0432.ccr-06-1426 pmid:17145841 fatcat:2uvugzhedjguzoljwgpuposkae